$BCDA
BioCardia, Inc.

2021 Q1 Form 10-Q Financial Statement

#000143774921011911 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $46.00K $38.00K
YoY Change 21.05% -82.41%
Cost Of Revenue $4.000K
YoY Change -96.23%
Gross Profit $46.00K $34.00K
YoY Change 35.29% -69.09%
Gross Profit Margin 100.0% 89.47%
Selling, General & Admin $1.177M $1.857M
YoY Change -36.62% 13.86%
% of Gross Profit 2558.7% 5461.76%
Research & Development $1.841M $2.786M
YoY Change -33.92% 28.62%
% of Gross Profit 4002.17% 8194.12%
Depreciation & Amortization $14.00K $22.00K
YoY Change -36.36% -4.35%
% of Gross Profit 30.43% 64.71%
Operating Expenses $3.018M $4.643M
YoY Change -35.0% 22.28%
Operating Profit -$2.972M -$4.609M
YoY Change -35.52% 25.01%
Interest Expense $0.00 $20.00K
YoY Change -100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $3.000K $15.00K
YoY Change -80.0% -31.82%
Pretax Income -$2.970M -$4.590M
YoY Change -35.29% 25.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.969M -$4.594M
YoY Change -35.37% 25.35%
Net Earnings / Revenue -6454.35% -12089.47%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$179.2K -$672.0K
COMMON SHARES
Basic Shares Outstanding 16.57M 6.848M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.50M $2.590M
YoY Change 730.12% -8.8%
Cash & Equivalents $21.50M $2.587M
Short-Term Investments
Other Short-Term Assets $340.0K $450.0K
YoY Change -24.44% 55.17%
Inventory
Prepaid Expenses
Receivables $190.0K $179.0K
Other Receivables $620.0K $0.00
Total Short-Term Assets $22.66M $3.219M
YoY Change 603.91% -8.76%
LONG-TERM ASSETS
Property, Plant & Equipment $164.0K $164.0K
YoY Change 0.0% -6.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.00K $54.00K
YoY Change -1.85% 0.0%
Total Long-Term Assets $649.0K $1.165M
YoY Change -44.29% -28.48%
TOTAL ASSETS
Total Short-Term Assets $22.66M $3.219M
Total Long-Term Assets $649.0K $1.165M
Total Assets $23.31M $4.384M
YoY Change 431.66% -14.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $850.0K $1.108M
YoY Change -23.29% -2.72%
Accrued Expenses $240.0K $99.00K
YoY Change 142.42% -83.39%
Deferred Revenue $1.180M $104.0K
YoY Change 1034.62% -11.86%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.750M $4.510M
YoY Change 5.32% 35.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.160M
YoY Change 13.73%
Total Long-Term Liabilities $0.00 $1.160M
YoY Change -100.0% 13.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.750M $4.510M
Total Long-Term Liabilities $0.00 $1.160M
Total Liabilities $4.746M $5.667M
YoY Change -16.25% 30.61%
SHAREHOLDERS EQUITY
Retained Earnings -$119.0M -$105.7M
YoY Change 12.66% 17.37%
Common Stock $17.00K $7.000K
YoY Change 142.86% -84.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.56M -$1.283M
YoY Change
Total Liabilities & Shareholders Equity $23.31M $4.384M
YoY Change 431.66% -14.99%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$2.969M -$4.594M
YoY Change -35.37% 25.35%
Depreciation, Depletion And Amortization $14.00K $22.00K
YoY Change -36.36% -4.35%
Cash From Operating Activities -$1.883M -$2.993M
YoY Change -37.09% 21.42%
INVESTING ACTIVITIES
Capital Expenditures $27.00K $5.000K
YoY Change 440.0% -90.91%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$27.00K -$5.000K
YoY Change 440.0% -90.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.000M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $2.005M
YoY Change
NET CHANGE
Cash From Operating Activities -$1.883M -2.993M
Cash From Investing Activities -$27.00K -5.000K
Cash From Financing Activities $2.005M
Net Change In Cash $95.00K -2.998M
YoY Change -103.17% 18.97%
FREE CASH FLOW
Cash From Operating Activities -$1.883M -$2.993M
Capital Expenditures $27.00K $5.000K
Free Cash Flow -$1.910M -$2.998M
YoY Change -36.29% 18.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2248000
CY2020Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2205000
CY2021Q1 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
851000
CY2020Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
961000
CY2021Q1 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
457000
CY2020Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
452000
CY2021Q1 bcda Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2021Q1 bcda Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
CY2021Q1 bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
CY2021Q1 bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
CY2021Q1 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000
CY2020Q4 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000
CY2021Q1 bcda Grant Liability Current
GrantLiabilityCurrent
610000
CY2020Q4 bcda Grant Liability Current
GrantLiabilityCurrent
615000
CY2021Q1 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
-146000
CY2020Q1 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
20000
CY2021Q1 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
CY2020Q1 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-146000
CY2021Q1 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
135000
CY2020Q1 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
118000
CY2021Q1 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
344000
CY2020Q4 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
401000
CY2020Q4 us-gaap Assets
Assets
23424000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
22659000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
22658000
CY2020Q1 bcda Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period
SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod
P3Y
CY2021Q1 bcda Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
66000
CY2020Q1 bcda Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
850000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
746000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
190000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
232000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
87000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1039000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1025000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137588000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135234000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
941000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
412000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
416000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
941000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
16000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
16000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3519732
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3547230
CY2021Q1 us-gaap Assets
Assets
23308000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
17000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
683000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
3018000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1180000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21502000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21407000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21407000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5585000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21502000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2587000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
95000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2998000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16792893
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16297381
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16792893
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16297381
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
4647000
CY2021Q1 us-gaap Depreciation
Depreciation
14000
CY2020Q1 us-gaap Depreciation
Depreciation
22000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
CY2021Q1 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
623000
CY2020Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
618000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
157000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
5000
CY2020Q1 us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
99000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-23000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
293000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
497000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-189000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
3000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
486000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
486000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2021Q1 us-gaap Liabilities
Liabilities
4746000
CY2020Q4 us-gaap Liabilities
Liabilities
4248000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23308000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23424000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2005000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1883000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2993000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2969000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4594000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2972000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4609000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
468000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
468000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
614000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
162000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
158000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
432000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
567000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1205
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P273D
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021Q1 us-gaap Other Operating Income
OtherOperatingIncome
4000
CY2020Q1 us-gaap Other Operating Income
OtherOperatingIncome
16000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
941000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1841000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2786000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119043000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116074000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1203000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1170000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
46000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
38000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1177000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1857000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
416000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
661430
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.29
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
125
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44643
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515036
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
18850
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
177100
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
423800
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1114306
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1086808
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.89
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.94
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.49
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.32
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.30
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.32
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.63
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
569000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
73000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y219D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y182D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y328D
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1580
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1934000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19176000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
18562000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2370000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1283000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"> &nbsp; <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(c)</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> &nbsp; &nbsp; <div style=" font-family: Times New Roman; font-size: 10pt; margin: 0pt;">&nbsp;</div> &nbsp; &nbsp; <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, derivative instruments, clinical accruals, inventory valuation, and assumptions used for revenue recognition.</div></div></div></div></div></div>
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16569268
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6831976

Files In Submission

Name View Source Status
0001437749-21-011911-index-headers.html Edgar Link pending
0001437749-21-011911-index.html Edgar Link pending
0001437749-21-011911.txt Edgar Link pending
0001437749-21-011911-xbrl.zip Edgar Link pending
bcda-20210331.xml Edgar Link completed
bcda-20210331.xsd Edgar Link pending
bcda-20210331_cal.xml Edgar Link unprocessable
bcda-20210331_def.xml Edgar Link unprocessable
bcda-20210331_lab.xml Edgar Link unprocessable
bcda-20210331_pre.xml Edgar Link unprocessable
bcda20210331_10q.htm Edgar Link pending
ex_230485.htm Edgar Link pending
ex_230486.htm Edgar Link pending
ex_230487.htm Edgar Link pending
ex_230488.htm Edgar Link pending
ex_247948.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending